Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People
NCT06976619Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of liraglutide in type 1 diabetes mellitus (T1D), type 2 diabetes mellitus (T2DM), sponsored by Mayo Clinic. Started Oct 2025; status: recruiting.
02
Drugs
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06976619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976619.